Posted inClinical Updates Hematology-Oncology
SELLAS Life Sciences’ Cancer Vaccine Galinpepimut-S Meets Primary Endpoint in Phase 3 AML Trial, Cutting Risk of Death by 41%
iStock, Alena Butusava NEW YORK — November 17, 2026 — SELLAS Life Sciences Group, Inc.…
